Ulcerative Colitis Study Aims to Restore a Healthy Balance in Gut Bacteria

Ulcerative Colitis Study Aims to Restore a Healthy Balance in Gut Bacteria
Seres Therapeutics, Inc., a company focused on the development of drugs targeting the unhealthy microbiome for the treatment of inflammatory, metabolic and infectious diseases, recently announced the initiation of a Phase 1b clinical trial to evaluate the efficacy, safety, and tolerability of the company’s therapeutic candidate SER-287 for the treatment of mild-to-moderate ulcerative colitis. SER-287,

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *